Single User License
INR 136060
Site License
INR 272120
Corporate User License
INR 408180

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Peritoneal Cancer-Pipeline Review, H1 2015

Peritoneal Cancer-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Peritoneal Cancer-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Peritoneal Cancer-Pipeline Review, H1 2015', provides an overview of the Peritoneal Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Peritoneal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Peritoneal Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Peritoneal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Peritoneal Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Peritoneal Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Peritoneal Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Peritoneal Cancer Overview 11

Therapeutics Development 12

Pipeline Products for Peritoneal Cancer-Overview 12

Pipeline Products for Peritoneal Cancer-Comparative Analysis 13

Peritoneal Cancer-Therapeutics under Development by Companies 14

Peritoneal Cancer-Therapeutics under Investigation by Universities/Institutes 19

Peritoneal Cancer-Pipeline Products Glance 20

Late Stage Products 20

Clinical Stage Products 21

Early Stage Products 22

Peritoneal Cancer-Products under Development by Companies 23

Peritoneal Cancer-Products under Investigation by Universities/Institutes 28

Peritoneal Cancer-Companies Involved in Therapeutics Development 29

AbbVie Inc. 29

Acceleron Pharma, Inc. 30

Adaptimmune Limited 31

Advanced Accelerator Applications SA 32

Amgen Inc. 33

Astellas Pharma Inc. 34

Astex Pharmaceuticals, Inc. 35

AstraZeneca PLC 36

Basilea Pharmaceutica AG 37

Bayer AG 38

BioMarin Pharmaceutical Inc. 39

Bionomics Limited 40

Boehringer Ingelheim GmbH 41

Celldex Therapeutics, Inc. 42

Celsion Corporation 43

Cerulean Pharma, Inc. 44

Clovis Oncology, Inc. 45

Corcept Therapeutics Incorporated 46

CritiTech, Inc. 47

CTI BioPharma Corp. 48

Eli Lilly and Company 49

Exelixis, Inc. 50

F. Hoffmann-La Roche Ltd. 51

Galena Biopharma, Inc. 52

Genelux Corporation 53

Genentech, Inc. 54

GlaxoSmithKline plc 55

Glycotope GmbH 56

Hemispherx Biopharma, Inc. 57

ImmunoGen, Inc. 58

Immunotope, Inc. 59

Immunovaccine, Inc. 60

Johnson & Johnson 61

Lee's Pharmaceutical Holdings Limited 62

MabVax Therapeutics Holdings, Inc. 63

MedImmune, LLC 64

Merck & Co., Inc. 65

Merrimack Pharmaceuticals, Inc. 66

NeoStem, Inc. 67

Novartis AG 68

Neovii Biotech GmbH 69

Oasmia Pharmaceutical AB 70

OBI Pharma, Inc. 71

Oncolytics Biotech Inc. 72

OncoMed Pharmaceuticals, Inc. 73

Onxeo SA 74

Oxford BioMedica plc 75

OXiGENE, Inc. 76

Pharma Mar, S.A. 77

Pharmacyclics, Inc. 78

PsiOxus Therapeutics, Ltd. 79

Recepta Biopharma S.A. 80

Sanofi Pasteur SA 81

Synta Pharmaceuticals Corp. 82

Takeda Oncology 83

TapImmune Inc. 84

TetraLogic Pharmaceuticals 85

TRACON Pharmaceuticals, Inc. 86

VentiRx Pharmaceuticals, Inc. 87

Peritoneal Cancer-Therapeutics Assessment 88

Assessment by Monotherapy Products 88

Assessment by Target 89

Assessment by Mechanism of Action 94

Assessment by Route of Administration 98

Assessment by Molecule Type 100

Drug Profiles 102

Pb-TCMC-Trastuzumab-Drug Profile 102

abexinostat hydrochloride-Drug Profile 104

abiraterone acetate-Drug Profile 106

ABT-767-Drug Profile 109

alisertib-Drug Profile 110

anetumab ravtansine-Drug Profile 114

AZD-1775-Drug Profile 116

AZD-2014-Drug Profile 118

AZD-5363-Drug Profile 120

BAL-101553-Drug Profile 122

belinostat-Drug Profile 123

bevacizumab-Drug Profile 126

binimetinib-Drug Profile 131

birinapant-Drug Profile 135

BNC-105P-Drug Profile 138

cabozantinib s-malate-Drug Profile 140

Cancer Stem Cell Therapy-Drug Profile 143

catumaxomab-Drug Profile 144

CDX-1401-Drug Profile 146

Cell Therapy to Target NY-ESO-1 and LAGE-1 for Oncology-Drug Profile 148

Cell Therapy to Target WT1 for Cancer-Drug Profile 150

CRLX-101-Drug Profile 151

dalantercept-Drug Profile 153

demcizumab-Drug Profile 155

Dendritic Cell Therapy for Cancer-Drug Profile 159

Dendritic Cell Therapy for Ovarian, Peritoneal and Fallopian Tube Cancer-Drug Profile 160

DMUC-4064A-Drug Profile 161

DPX-Survivac-Drug Profile 162

EGEN-001-Drug Profile 165

elesclomol-Drug Profile 167

enadenotucirev-Drug Profile 169

erismodegib-Drug Profile 171

fosbretabulin tromethamine-Drug Profile 174

GALE-301-Drug Profile 178

ganetespib-Drug Profile 180

gimatecan-Drug Profile 184

GLONC-1-Drug Profile 186

guadecitabine-Drug Profile 189

IMGN-853-Drug Profile 192

IMT-1012-Drug Profile 193

ipafricept-Drug Profile 194

LCL-161-Drug Profile 195

lifastuzumab vedotin-Drug Profile 197

linsitinib-Drug Profile 199

LY-2606368-Drug Profile 201

MesoCART-Drug Profile 202

mifepristone-Drug Profile 203

MK-2206-Drug Profile 205

Monoclonal Antibody Conjugate to Target B7-H3 for Cancer-Drug Profile 208

motolimod-Drug Profile 209

MV-NIS-Drug Profile 211

nintedanib-Drug Profile 213

NSC-748933-Drug Profile 217

OBI-822/821-Drug Profile 218

olaratumab-Drug Profile 220

paclitaxel-Drug Profile 222

paclitaxel-Drug Profile 224

paclitaxel poliglumex-Drug Profile 225

PankoMab-GEX-Drug Profile 229

pazopanib hydrochloride-Drug Profile 230

pelareorep-Drug Profile 235

ralimetinib mesylate-Drug Profile 240

ramucirumab-Drug Profile 241

RebmAb-100-Drug Profile 246

regorafenib-Drug Profile 248

rintatolimod-Drug Profile 251

rucaparib phosphate-Drug Profile 252

selumetinib sulfate-Drug Profile 255

seribantumab-Drug Profile 258

SG-2000-Drug Profile 260

sofituzumab vedotin-Drug Profile 262

sorafenib tosylate-Drug Profile 263

talazoparib-Drug Profile 267

Theranean-Drug Profile 269

TPIV-200-Drug Profile 270

trabectedin-Drug Profile 272

TRC-105-Drug Profile 275

trebananib-Drug Profile 277

TroVax-Drug Profile 280

Vaccine for Oncology-Drug Profile 283

Vaccine to Target Carcinoembryonic Antigen for Oncology-Drug Profile 284

vCP-2292-Drug Profile 285

X-82-Drug Profile 286

Peritoneal Cancer-Recent Pipeline Updates 287

Peritoneal Cancer-Dormant Projects 428

Peritoneal Cancer-Discontinued Products 429

Peritoneal Cancer-Product Development Milestones 430

Featured News & Press Releases 430

Appendix 433

Methodology 433

Coverage 433

Secondary Research 433

Primary Research 433

Expert Panel Validation 433

Contact Us 434

Disclaimer 434

List of Tables

Number of Products under Development for Peritoneal Cancer, H1 2015 17

Number of Products under Development for Peritoneal Cancer-Comparative Analysis, H1 2015 18

Number of Products under Development by Companies, H1 2015 20

Number of Products under Development by Companies, H1 2015 (Contd..1) 21

Number of Products under Development by Companies, H1 2015 (Contd..2) 22

Number of Products under Development by Companies, H1 2015 (Contd..3) 23

Number of Products under Investigation by Universities/Institutes, H1 2015 24

Comparative Analysis by Late Stage Development, H1 2015 25

Comparative Analysis by Clinical Stage Development, H1 2015 26

Comparative Analysis by Early Stage Development, H1 2015 27

Products under Development by Companies, H1 2015 28

Products under Development by Companies, H1 2015 (Contd..1) 29

Products under Development by Companies, H1 2015 (Contd..2) 30

Products under Development by Companies, H1 2015 (Contd..3) 31

Products under Development by Companies, H1 2015 (Contd..4) 32

Products under Investigation by Universities/Institutes, H1 2015 33

Peritoneal Cancer-Pipeline by AbbVie Inc., H1 2015 34

Peritoneal Cancer-Pipeline by Acceleron Pharma, Inc., H1 2015 35

Peritoneal Cancer-Pipeline by Adaptimmune Limited, H1 2015 36

Peritoneal Cancer-Pipeline by Advanced Accelerator Applications SA, H1 2015 37

Peritoneal Cancer-Pipeline by Amgen Inc., H1 2015 38

Peritoneal Cancer-Pipeline by Astellas Pharma Inc., H1 2015 39

Peritoneal Cancer-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 40

Peritoneal Cancer-Pipeline by AstraZeneca PLC, H1 2015 41

Peritoneal Cancer-Pipeline by Basilea Pharmaceutica AG, H1 2015 42

Peritoneal Cancer-Pipeline by Bayer AG, H1 2015 43

Peritoneal Cancer-Pipeline by BioMarin Pharmaceutical Inc., H1 2015 44

Peritoneal Cancer-Pipeline by Bionomics Limited, H1 2015 45

Peritoneal Cancer-Pipeline by Boehringer Ingelheim GmbH, H1 2015 46

Peritoneal Cancer-Pipeline by Celldex Therapeutics, Inc., H1 2015 47

Peritoneal Cancer-Pipeline by Celsion Corporation, H1 2015 48

Peritoneal Cancer-Pipeline by Cerulean Pharma, Inc., H1 2015 49

Peritoneal Cancer-Pipeline by Clovis Oncology, Inc., H1 2015 50

Peritoneal Cancer-Pipeline by Corcept Therapeutics Incorporated, H1 2015 51

Peritoneal Cancer-Pipeline by CritiTech, Inc., H1 2015 52

Peritoneal Cancer-Pipeline by CTI BioPharma Corp., H1 2015 53

Peritoneal Cancer-Pipeline by Eli Lilly and Company, H1 2015 54

Peritoneal Cancer-Pipeline by Exelixis, Inc., H1 2015 55

Peritoneal Cancer-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 56

Peritoneal Cancer-Pipeline by Galena Biopharma, Inc., H1 2015 57

Peritoneal Cancer-Pipeline by Genelux Corporation, H1 2015 58

Peritoneal Cancer-Pipeline by Genentech, Inc., H1 2015 59

Peritoneal Cancer-Pipeline by GlaxoSmithKline plc, H1 2015 60

Peritoneal Cancer-Pipeline by Glycotope GmbH, H1 2015 61

Peritoneal Cancer-Pipeline by Hemispherx Biopharma, Inc., H1 2015 62

Peritoneal Cancer-Pipeline by ImmunoGen, Inc., H1 2015 63

Peritoneal Cancer-Pipeline by Immunotope, Inc., H1 2015 64

Peritoneal Cancer-Pipeline by Immunovaccine, Inc., H1 2015 65

Peritoneal Cancer-Pipeline by Johnson & Johnson, H1 2015 66

Peritoneal Cancer-Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015 67

Peritoneal Cancer-Pipeline by MabVax Therapeutics Holdings, Inc., H1 2015 68

Peritoneal Cancer-Pipeline by MedImmune, LLC, H1 2015 69

Peritoneal Cancer-Pipeline by Merck & Co., Inc., H1 2015 70

Peritoneal Cancer-Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 71

Peritoneal Cancer-Pipeline by NeoStem, Inc., H1 2015 72

Peritoneal Cancer-Pipeline by Novartis AG, H1 2015 73

Peritoneal Cancer-Pipeline by Neovii Biotech GmbH, H1 2015 74

Peritoneal Cancer-Pipeline by Oasmia Pharmaceutical AB, H1 2015 75

Peritoneal Cancer-Pipeline by OBI Pharma, Inc., H1 2015 76

Peritoneal Cancer-Pipeline by Oncolytics Biotech Inc., H1 2015 77

Peritoneal Cancer-Pipeline by OncoMed Pharmaceuticals, Inc., H1 2015 78

Peritoneal Cancer-Pipeline by Onxeo SA, H1 2015 79

Peritoneal Cancer-Pipeline by Oxford BioMedica plc, H1 2015 80

Peritoneal Cancer-Pipeline by OXiGENE, Inc., H1 2015 81

Peritoneal Cancer-Pipeline by Pharma Mar, S.A., H1 2015 82

Peritoneal Cancer-Pipeline by Pharmacyclics, Inc., H1 2015 83

Peritoneal Cancer-Pipeline by PsiOxus Therapeutics, Ltd., H1 2015 84

Peritoneal Cancer-Pipeline by Recepta Biopharma S.A., H1 2015 85

Peritoneal Cancer-Pipeline by Sanofi Pasteur SA, H1 2015 86

Peritoneal Cancer-Pipeline by Synta Pharmaceuticals Corp., H1 2015 87

Peritoneal Cancer-Pipeline by Takeda Oncology, H1 2015 88

Peritoneal Cancer-Pipeline by TapImmune Inc., H1 2015 89

Peritoneal Cancer-Pipeline by TetraLogic Pharmaceuticals, H1 2015 90

Peritoneal Cancer-Pipeline by TRACON Pharmaceuticals, Inc., H1 2015 91

Peritoneal Cancer-Pipeline by VentiRx Pharmaceuticals, Inc., H1 2015 92

Assessment by Monotherapy Products, H1 2015 93

Number of Products by Stage and Target, H1 2015 95

Number of Products by Stage and Mechanism of Action, H1 2015 100

Number of Products by Stage and Route of Administration, H1 2015 104

Number of Products by Stage and Molecule Type, H1 2015 106

Peritoneal Cancer Therapeutics-Recent Pipeline Updates, H1 2015 292

Peritoneal Cancer-Dormant Projects, H1 2015 432

Peritoneal Cancer-Discontinued Products, H1 2015 433

List of Figures

Number of Products under Development for Peritoneal Cancer, H1 2015 17

Number of Products under Development for Peritoneal Cancer-Comparative Analysis, H1 2015 18

Number of Products under Development by Companies, H1 2015 19

Comparative Analysis by Late Stage Development, H1 2015 25

Comparative Analysis by Clinical Stage Development, H1 2015 26

Assessment by Monotherapy Products, H1 2015 93

Number of Products by Top 10 Targets, H1 2015 94

Number of Products by Stage and Top 10 Targets, H1 2015 94

Number of Products by Top 10 Mechanism of Actions, H1 2015 99

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 99

Number of Products by Top 10 Routes of Administration, H1 2015 103

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 103

Number of Products by Top 10 Molecule Types, H1 2015 105

Number of Products by Stage and Top 10 Molecule Types, H1 2015 105

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc.

Acceleron Pharma, Inc.

Adaptimmune Limited

Advanced Accelerator Applications SA

Amgen Inc.

Astellas Pharma Inc.

Astex Pharmaceuticals, Inc.

AstraZeneca PLC

Basilea Pharmaceutica AG

Bayer AG

BioMarin Pharmaceutical Inc.

Bionomics Limited

Boehringer Ingelheim GmbH

Celldex Therapeutics, Inc.

Celsion Corporation

Cerulean Pharma, Inc.

Clovis Oncology, Inc.

Corcept Therapeutics Incorporated

CritiTech, Inc.

CTI BioPharma Corp.

Eli Lilly and Company

Exelixis, Inc.

F. Hoffmann-La Roche Ltd.

Galena Biopharma, Inc.

Genelux Corporation

Genentech, Inc.

GlaxoSmithKline plc

Glycotope GmbH

Hemispherx Biopharma, Inc.

ImmunoGen, Inc.

Immunotope, Inc.

Immunovaccine, Inc.

Johnson & Johnson

Lee's Pharmaceutical Holdings Limited

MabVax Therapeutics Holdings, Inc.

MedImmune, LLC

Merck & Co., Inc.

Merrimack Pharmaceuticals, Inc.

NeoStem, Inc.

Novartis AG

Neovii Biotech GmbH

Oasmia Pharmaceutical AB

OBI Pharma, Inc.

Oncolytics Biotech Inc.

OncoMed Pharmaceuticals, Inc.

Onxeo SA

Oxford BioMedica plc

OXiGENE, Inc.

Pharma Mar, S.A.

Pharmacyclics, Inc.

PsiOxus Therapeutics, Ltd.

Recepta Biopharma S.A.

Sanofi Pasteur SA

Synta Pharmaceuticals Corp.

Takeda Oncology

TapImmune Inc.

TetraLogic Pharmaceuticals

TRACON Pharmaceuticals, Inc.

VentiRx Pharmaceuticals, Inc.

Peritoneal Cancer Therapeutic Products under Development, Key Players in Peritoneal Cancer Therapeutics, Peritoneal Cancer Pipeline Overview, Peritoneal Cancer Pipeline, Peritoneal Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com